Elisabetta B.
- Country
- Italy
- Department
- S.C. Gastroenterologia
Research Overview
- N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa in Adults with Biopsy‑Confirmed F2–F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa Safety and Tolerability in Adults with F2‑F3 Metabolic Dysfunction‑Associated Steatohepatitis
Data & Insights
Has run more than one trial at 168 of 295 partner sites.
Specializations
Liver Disease Management
The investigator specializes in treating advanced forms of non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), with particular focus on patients with varying stages of liver fibrosis and cirrhosis.
- Pre-cirrhotic liver conditions
- Compensated cirrhosis
- Fibrosis progression
Their work encompasses both early-stage interventions and management of advanced liver disease complications.
Metabolic Health
The investigator focuses on the intersection of metabolic dysfunction and liver health, addressing conditions associated with insulin resistance and metabolic risk factors.
- Hepatic steatosis
- Metabolic syndrome
- Liver inflammation
Their expertise extends to treating complex metabolic conditions affecting liver function.
Therapeutic Innovation
The investigator evaluates novel therapeutic approaches for liver diseases, including targeted molecular therapies and innovative treatment compounds for hepatic fibrosis.
- Liver disease progression
- Clinical outcomes assessment
- Hepatic regeneration
Their work includes evaluating treatments for both early-stage and advanced liver conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.